What is LGD-3303?
LGD-3303 is a SARM developed by Ligand Pharmaceuticals with a different chemical structure to LGD-4033. While LGD-4033 is a partial agonist, LGD-3303 is reported to act as a full agonist at androgen receptors in muscle and a partial agonist in bone. This distinction is of research interest for studying tissue-specific androgen receptor modulation.
⚠ Research Purposes Only: LGD-3303 is a research chemical with no human clinical trial data. It is not approved for human consumption by the FDA or MHRA.
LGD-3303 vs LGD-4033 — Research Comparison
| Parameter | LGD-3303 | LGD-4033 |
|---|---|---|
| AR Activity | Full agonist (muscle) | Full agonist |
| Human Trial Data | None published | Phase I complete |
| Half-Life (est.) | ~6 hours | 24–36 hours |
| Research Maturity | Preclinical | Clinical |
| Availability | Limited | Widely available |
Preclinical Research Findings
Animal model research on LGD-3303 showed potent anabolic effects with partial androgenic effects in prostate tissue — consistent with the SARM selectivity goal. However, without published human clinical trials, extrapolation of animal data to human research contexts must be done with appropriate caution.
Key Research Consideration
LGD-3303's shorter half-life (~6 hours vs 24–36 for LGD-4033) may require different administration frequency in research protocols. Its full agonist classification in muscle tissue makes it of interest for comparative androgen receptor research alongside partial agonist SARMs.
🔬 Where to Source LGD-3303 for Research (USA & UK)
For USA and UK researchers, BehemothLabz is one of the most reliable sources with third-party certificates of analysis. All products are for research purposes only and not approved for human consumption.
Visit BehemothLabz →⚠ Affiliate link — use code Tomjunkie for 20% off. Research purposes only.
Frequently Asked Questions
LGD-3303 is a SARM developed by Ligand Pharmaceuticals, distinct from LGD-4033. It is reported as a full agonist at muscle androgen receptors. It is a research chemical with no published human clinical trials.
LGD-3303 has a shorter half-life (~6 hours vs 24–36 hours), different agonist classification, and no published human trial data compared to LGD-4033's completed Phase I trial.
There is insufficient published human data to make this comparison. Preclinical models suggest high anabolic potency but no direct human comparison studies exist.
BehemothLabz stocks LGD-3303 with certificates of analysis. For research purposes only.